Home › Research › Cognitive tests and assessment
Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH et al.. Journal of clinical pharmacy and therapeutics, 2010-10-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
What is known Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer's disease (AD). Objective The goal of this study was to assess the efficacy of saffron in the treatment of mild to moderate AD.
What this study adds
Evidence grade: High
This is a trial. In this 16-week double-blind placebo-controlled trial, 46 people with probable mild to moderate Alzheimer's disease were given saffron or placebo to assess its efficacy. The text provided does not report the results, so no conclusion about treating, curing, or preventing Alzheimer's disease can be drawn from it.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Akhondzadeh, S., Sabet, M. S., Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., et al. (2010). Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. Journal of clinical pharmacy and therapeutics. https://doi.org/10.1111/j.1365-2710.2009.01133.x
Vancouver
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. Journal of clinical pharmacy and therapeutics. 2010. doi:10.1111/j.1365-2710.2009.01133.x. PMID: 20831681.
BibTeX
@article{akhondzadeh2010-20831681,
author = {Akhondzadeh, S. and Sabet, M. S. and Harirchian, M. H. and Togha, M. and Cheraghmakani, H. and Razeghi, S. and SSh, Hejazi and Yousefi, M. H. and others},
title = {{Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial}},
journal = {Journal of clinical pharmacy and therapeutics},
year = {2010},
doi = {10.1111/j.1365-2710.2009.01133.x},
pmid = {20831681},
url = {https://doi.org/10.1111/j.1365-2710.2009.01133.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer's disease (AD).
- Objective The goal of this study was to assess the efficacy of saffron in the treatment of mild to moderate AD.
- Methods Forty-six patients with probable AD were screened for a 16-week, double-blind study of parallel groups of patients with mild to moderate AD.
- The psychometric measures, which included AD assessment scale-cognitive subscale (ADAS-cog), and clinical dementia rating scale-sums of boxes, were performed to monitor the global cognitive and clinical profiles of the patients.
Why it matters
In this 16-week double-blind placebo-controlled trial, 46 people with probable mild to moderate Alzheimer's disease were given saffron or placebo to assess its efficacy. The text provided does not report the results, so no conclusion about treating, curing, or preventing Alzheimer's disease can be drawn from it.
Study details
- Evidence strengthHigh
How this study scored 60/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 58 of the 96 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of clinical pharmacy and therapeutics) |
| Journal's citation record | 1 / 4 | Journal of Clinical Pharmacy and Therapeutics: journal h-index 100 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 250 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.9 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 3 / 6 | Cited 3.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 42 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Tehran University of Medical Sciences: institution h-index 810 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20831681) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 58 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 58 of the 96 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/j.1365-2710.2009.01133.x
- PubMed: 20831681
- Original source →
- Free full text: Journal of Clinical Pharmacy and Therapeutics →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.